Glutamine and its derivatives in the correction of metabolic disorders in HIV-infected patients (review)

Cover Page

Cite item

Full Text

Abstract

It has been established that HIV-infection is associated with progressive deficiency of L-glutamine followed by immune dysfunction, reduced body mass and muscle strength, morphological disorders and functional disintegration of the intestine, as well as neurological disorders. According to current ideas, correction of L-glutamine deficiency is one of the important components of adjuvant therapy for HIV-infected patients within general nutritional support strategy. This measure helps to slow development of AIDS, reduce side effects of antiretroviral therapy and enhance effectiveness.

About the authors

Valery V. Luft

Saint-Petersburg institute of emergency care n.a. I.I. Dzhanelidze

Author for correspondence.
Email: Lvm_aspep@mail.ru
SPIN-code: 2003-5693

д.м.н., профессор, руководитель лаборатории клинического питания

Russian Federation, 3, Budapeshtskaya street, Saint-Petersburg, 192242

Alexander V. Dmitriev

Saint - Petersburg institute of emergency care n.a. I.I.Dzhanelidze

Email: avd.dmitriev@gmail.com

д.м.н., клинический фармаколог, эксперт Северо-Западной ассоциации парентерального и энтерального питания

Russian Federation, 3, Budapeshtskaya street, Saint-Petersburg, 192242

References

  1. Rajendram R, Preedy VR, Patel VB. Glutamine in clinical nutrition. Springer New York Heidelberg Dordrecht London. 2015. 521 p. https://doi.org/10.1007/978-1-4939-1932-1.
  2. Macintosh HD. The importance of glutamine and antioxidant vitamin supplementation in HIV. Nemechek Health Renewal. Dedicated HIV Care; 2007. Pp. 1−8.
  3. Shabert JK, Wilmore DW. Glutamine deficiency as a cause of human immunodeficiency virus wasting. Med Hypotheses. 1996;46(3):252−256. doi: 10.1016/s0306-9877(96) 90251-0.
  4. Noyer CM, Simon D, Borczuk A, et al. A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. Am J Gastroenterol. 1998;93:972−975. doi: 10.1111/j.1572-0241.1998.00290.x.
  5. Dudgeon WD, Phillips KD, Carson JA, et al. Counteracting muscle wasting in HIV-infected individuals. British HIV Association HIV Medicine. 2006;7(5):299−310. doi: 10.1111/j.1468-1293.2006.00380.x.
  6. Ockenga J, Grimble R, Jonkers-Schuitema C, et al. ESPEN guidelines on enteral nutrition: Wasting in HIV and other chronic infectious diseases. Clinical Nutrition. 2006;25(2):319–329. doi: 10.1016/j.clnu.2006.01.016.
  7. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001;358(9290): 1322−1327. doi: 10.1016/s0140-6736(01)06413-3.
  8. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. J Parent Enteral Nutr. 2000;24:133−139. doi: 10.1177/ 0148607100024003133.
  9. Bushen OY, Davenport JA, Lima AB, et al. Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in Northeast Brazil. Clin Infect Dis. 2004;38(12):1764−1770. doi: 10.1086/421394.
  10. Amara S. Oral Glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Ann Pharmacother. 2008;42(10):1481−1485. doi: 10.1345/aph.1L179.
  11. Leite RD, Lima NL, Leite CA, et al. Improvement of intestinal permeability with Alanyl-Glutamine in HIV patients: a randomized, double blinded, placebo-controlled clinical trial. Arq Gastroenterol. 2013;50(1):56−63. doi: 10.1590/s0004-28032013000100011.
  12. Shabert JK, Wilmore DW. Glutamine deficiency as a cause of human immunodeficiency virus wasting. Med Hypotheses. 1996;46(3):252−256. doi: 10.1016/s0306-9877(96) 90251-0.
  13. Soares RL, Coura LC, Magalhães LF, et al. Study of the correlation between nutritional status and histomorphometric abnormalities of the jejunum mucosa in HIV infected patients. Gastroenterol. Endosc Dig. 1996;15:1−6.
  14. Hsu JW, Pencharz PB, Macallan D, Tomkins A. Macronutrients and HIV/AIDS: a review of current evidence. WHO: Department of Nutrition; 2005. 19 p.
  15. Drain PK, Kupka R, Mugusi F, Fawzi WW. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr. 2007;85(2):333–345. doi: 10.1093/ajcn/85.2.333.
  16. Bonetto A, Penna F, Minero VG, et al. Glutamine prevents myostatinhyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-α. Amino Acids. 2011;40(2):585−594. doi: 10.1007/s00726-010-0683-3.
  17. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011;2(3):143−151. doi: 10.1007/s13539-011-0035-5.
  18. Макаров А.Ю., Чикова Р.С., Улюкин И.М., Помников В.Г. Неврологические синдромы при ВИЧ-инфекции // Неврологический журнал. — 2004. — Т. 9. — № 5. — С. 45. [Makarov AYu, Chikova RS, Ulyukin IM, Pomnikov VG. Neurological syndromes of HIV infection. Journal of neurology. 2004;9(5):45. (In Russ).]
  19. Ferrari S, Vento S, Monaco S, et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc. 2006;81(2): 213–219. doi: 10.4065/81.2.213.
  20. Соловьева Е.Т., Дубовская С.С. ВИЧ-инфекция в неврологической практике: актуальные вопросы // Острые и неотложные состояния в практике врача. — 2010. — № 2. — С. 46−51. [Solov’eva ET, Dubovskaia SS. VICH-infektsiia v nevrologicheskoi praktike: aktual’nye voprosy. Ostrye i neotlozhnye sostoianiia v praktike vracha. 2010;(2):46−51. (In Russ).]
  21. Erecinska M, Zaleska M, Nelson D, et al. Neuronal glutamine utilization: glutamine/glutamate homeostasis in synaptosomes. J Neurochem. 1990;54(6):2057–2069. doi: 10.1111/j.1471-4159.1990.tb04911.x.
  22. Daikhin Y. Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr. 2000; 130(4S Suppl):1026S−1031S. doi: 10.1093/jn/130.4.1026S.
  23. Gras G, Porcheray F, Samah B, Leone C. The glutamate-glutamine cycle as an inducible, protective face of macrophage activation. J Leukoc Biol. 2006;80(5):1067−1075. doi: 10.1189/jlb.0306153.
  24. Garvey L, Winston A, Walsh J, et al. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol. 2011,18(3):527−534. doi: 10.1111/j.1468-1331.2010.03291.x.
  25. Wright E. Neurocognitive impairment and neuroCART. Curr Opin HIV AIDS. 2011;6(4):303−308. doi: 10.1097/COH.0b013e3283477c46.
  26. Takahashi M, Billups B, Rossi D, et al. The role of glutamate transporters in glutamate homeostasis in the brain. J Exp Biol. 1977;200(Pt 2):401–409.
  27. Danbolt NC. The high affinity uptake system for excitatory amino acids in the brain. Prog Neurobiol. 1994;44(4): 377–396. doi: 10.1016/0301-0082(94)90033-7.
  28. Breitbart W. A clinical guide to supportive and palliative care for HIV/AIDS. Chapter 4: Pain’, HIV/AIDS Bureau, Health Resources and Services Administration, U.S. Department of Health and Human Services; 2003.
  29. Roth E. Immune and cell modulation by amino acids. Clin Nutr. 2007;26(5):535–544. doi: 10.1016/j.clnu.2007.05.007.
  30. Roth E. Nonnutritive effects of glutamine. J Nutr. 2008;138(10):2025S–2031S. doi: 10.1093/jn/138.10.2025S.
  31. Harris RC, Hoffman JR, Allsopp A, Routledge NB. L-glutamine absorption is enhanced after ingestion of L-alanylglutamine compared with the free amino acid or wheat protein. Nutr Res. 2012;32(4):272−277. doi: 10.1016/ j.nutres.2012.02.003.
  32. Shabert JK, Winslow C, Lacey JM, Wilmore DW. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition. 1999;15(11−12):860−864. doi: 10.1016/s0899-9007(99)00213-0.
  33. Huffman FG, Walgren ME. L-glutamine supplementation improves nelfinavir-associated diarrhea in HIV-infected individuals. HIV Clin Trials. 2003;4(5):324−329. doi: 10.1310/BFDT-J2GH-27L7-905G.
  34. Heiser CR, Ernst JA, Barrett JT, et al. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care (Chic). 2004;3(4):121−129. doi: 10.1177/154510970400300403.
  35. Guidelines for the use of antiretroviral agents in pediatric HIV infection. August 11, 2011. Available from: https://aidsinfo.nih.gov/contentfiles/PediatricGuidelines003005.pdf.
  36. NageliM, Fasshauer M, Sommerfeld J, et al. Prolonged continuous intravenous infusion of the dipeptide L-alanine-L-glutamine significantly increases plasma glutamine and alanine without elevating brain glutamate in patients with severe traumatic brain injury. Critical Care. 2014;18(4):139−150. doi: 10.1186/cc13962.
  37. Pires VL, Souza JR, Guimarães SB, et al. Preconditioning with L-alanyl-L-glutamine in a Mongolian gerbil model of acute cerebral ischemia/reperfusion injury. Acta Cir Bras. 2011;26 (Suppl 1):14−20. doi: 10.1590/s0102-86502011000700004.
  38. Jain P, Khanna NK. Evaluation of anti-inflammatory and analgesic properties of L-Glutamine. Agents Actions. 1981;11(3):243−249. doi: 10.1007/bf01967621.
  39. Owen MD, Unal CB, Callahan MF, et al. Glycyl-glutamine inhibits the respiratory depression, but not the antinociception, produced by morphine. Am J Physiol. 2000;279(5):R1944–R1948. doi: 10.1152/ajpregu.2000. 279.5.R1944.
  40. Cavun S, Goktalay G, Millington WR. Glycyl-glutamine, an endogenous β-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal. J Pharmacol Experim Ther. 2005;315(2):949−958. doi: 10.1124/jpet.105.091553.
  41. Krashin DL, Merrill JO, Trescot AM. Opioids in the management of HIV-related pain. Pain Physician. 2012; 15(3 Suppl):ES157-ES168.
  42. Serrano-Villar S, et al. Targeting gut mucosa in HIV+ subjects with prebiotics and glutamine: a pilot clinical trial. workshop: inflammation and chronic hepatitis/hiv infections: who is the driver? Milan, Italy; 2014.
  43. Patrick L. Nutrients and HIV: Part Three — N-acetylcysteine, alpha-lipoic acid, L-glutamine, and L-carnitine. Alternative Med Rev. 2000;5(4): 290−305.
  44. Newsholme Ph, Procopio J, Ramos Lima MM, et al. Glutamine and glutamate — their central role in cell metabolism and function. Cell Biochem Funct. 2003;21(1):1–9. doi: 10.1002/cbf.1003.
  45. https://doi.org/10.36425/clinnutrit20650

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Scheme of changes in the metabolism of L-glutamine in healthy and HIV-infected people (according to H. Macintosh, 2007 [2])

Download (867KB)
Indexing metadata
3. Fig. 2. Dynamics of changes in the concentration of L-glutamine in the blood plasma of healthy volunteers (μmol ∙ l-1, ordinate axis) after a single injection (clock, abscissa axis) of L-glutamine 60 mg / kg (left) and L-alanyl-L- dipeptide glutamine 89 mg / kg (left side of the right graph)

Download (442KB)
Indexing metadata

Copyright (c) 2020 Luft V.V., Dmitriev A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies